{
    "clinical_study": {
        "@rank": "6698", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Experimental", 
                "description": "40 subjects administered placebo"
            }, 
            {
                "arm_group_label": "Testosterone + Buspirone", 
                "arm_group_type": "Experimental", 
                "description": "40 subjects administered 0.5 mg Testosterone + 10 mg Buspirone hydrochloride"
            }
        ], 
        "brief_summary": {
            "textblock": "A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety\n      and efficacy of Lybridos in the domestic setting in healthy female subjects with hypoactive\n      sexual desire disorder and maladaptive activity of sexual inhibitory mechanisms.\n\n      This is a 2-arm placebo and Lybridos (0.5 mg testosterone + buspirone 10 mg) extension to\n      study EB90 (Clinical Study Protocol EB90a, version 3.0, 07 June 2013).\n\n      In the present study, the efficacy of Lybridos will be evaluated in the domestic setting in\n      healthy female subjects with HSDD and maladaptive activity of sexual inhibitory\n      mechanism(s). Sexual satisfaction and other aspects of sexual functioning will be measured\n      within 24 hours after each sexual activity. The following hypotheses will be tested:\n\n      Lybridos, as compared to placebo, will significantly increase the number of satisfying\n      sexual events.\n\n      Objectives:\n\n      To investigate the efficacy of Lybridos as compared to placebo in increasing the number of\n      satisfactory sexual episodes in healthy female subjects with hypoactive sexual desire\n      disorder (HSDD) and maladaptive activity of sexual inhibitory mechanisms\n\n        -  To identify the optimal dose of Lybridos to take into phase 3 clinical development\n\n        -  To confirm that Lybridos has superior efficacy as compared to testosterone alone and to\n           buspirone alone\n\n        -  To evaluate the effect of Lybridos as measured by scales of sexual satisfaction and/or\n           sexual desire/arousal\n\n        -  To evaluate the safety profile of Lybridos"
        }, 
        "brief_title": "Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypoactive Sexual Desire Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Sexual Dysfunctions, Psychological", 
                "Hypokinesia"
            ]
        }, 
        "detailed_description": {
            "textblock": "None entered"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must meet all of the following criteria:\n\n          1. Provision of written informed consent\n\n          2. Females between 21 and 70 years of age, inclusive, pre  or postmenopausal, with HSDD\n             (comorbidity with female sexual arousal disorder [FSAD] and/or female orgasmic\n             disorder [FOD; only as secondary diagnosis] is allowed).  The diagnosis of HSDD will\n             be established by a trained health care professional.\n\n          3. Maladaptive activity of sexual inhibitory mechanism(s) (see appendix 4 for\n             definition)\n\n          4. Be involved in a stable relationship and have a partner who will be at home for the\n             majority of the study duration\n\n          5. Healthy according to normal results of medical history, physical examination,\n             laboratory values, and vital signs; exceptions may be made if the investigator\n             considers an abnormality to be clinically irrelevant\n\n        Exclusion Criteria:\n\n        Subjects who meet any of the following criteria are not eligible to participate in the\n        study:\n\n        Cardiovascular Conditions\n\n          1. Any underlying cardiovascular condition, including unstable angina pectoris, that\n             would preclude sexual activity\n\n          2. Systolic blood pressure \u2265 140 mmHg and/or diastolic blood pressure > 90 mmHg.  For\n             subjects \u2265 60 years old and without diabetes mellitus, familial hypercholesterolemia,\n             or cardiovascular disease: systolic blood pressure \u2265 160 mmHg and/or diastolic blood\n             pressure \u2265 90 mmHg\n\n          3. Systolic blood pressure \u2264  90 mmHg and/or diastolic blood pressure \u2264  50 mmHg\n             Gynecological and Obstetric Conditions\n\n          4. Use of any contraceptive containing anti-androgens (e.g. Cyproteron acetate) or\n             (anti)androgenic progestogens (drospirenone, dienogest, chlormadinone acetate and\n             norgestrel)\n\n          5. Use of any contraceptive or hormone replacement therapy (HRT) containing more than 50\n             \u03bcg/day of estrogen\n\n          6. Positive test result for Chlamydia or gonorrhea\n\n          7. Pregnancy or intention to become pregnant during this study (Note: A urine pregnancy\n             test will be performed in all women of child bearing potential prior to the\n             administration of study medications.)\n\n          8. Lactating or delivery in the previous 6 months prior to signing Informed Consent Form\n\n          9. Significant abnormal Pap smear in the previous 12 months prior to signing Informed\n             Consent Form\n\n         10. History of bilateral oophorectomy\n\n         11. Other unexplained gynecological complaints, such as clinically relevant abnormal\n             uterine bleeding patterns\n\n         12. Perimenopausal status (cycle shortening/irregular menstrual bleeding in the last 12\n             consecutive months and/or occurrence of vasomotor symptoms (e.g. hot flashes, night\n             sweating) in combination with elevated FSH levels (>40 IU/L) for women from age 40\n             onwards; in women with a history of hysterectomy perimenopausality can be assessed by\n             FSH levels (>40 IU/L) and/or vasomotor symptoms Other Medical Conditions\n\n         13. Liver and/or renal insufficiency (aspartate aminotransferase, alanine\n             aminotransferase and gamma glutamyltransferase > 3 times the upper limit of normal\n             and/or estimated glomerular filtration rate (eGFR) < 60.00 mL/min based on the\n             Cockcroft Gault formula)\n\n         14. Any current endocrine disease or endocrinopathy (e.g. uncontrolled thyroid\n             dysfunction) as determined by medical history, basic physical examination and/or\n             laboratory values significantly outside the normal range of the central laboratory;\n             or uncontrolled diabetes mellitus(HbA1c > 7.5%)\n\n         15. Free- and/or total testosterone levels outside the upper limit of the reference range\n             of the central laboratory (free testosterone:  > 1.1 ng/dL, and total testosterone >\n             80 ng/dL)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101203", 
            "org_study_id": "EB90a extension"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Solid Oral Dosage. Maximum every other day (on an as needed basis)"
            }, 
            {
                "arm_group_label": "Testosterone + Buspirone", 
                "intervention_name": "0.5 mgTestosterone + 10 mg Buspirone", 
                "intervention_type": "Drug", 
                "other_name": "Solid Oral Dosage. Maximum every other day (on an as needed basis)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Buspirone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "HSDD", 
        "lastchanged_date": "March 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92120"
                    }, 
                    "name": "San Diego Sexual Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34208"
                    }, 
                    "name": "Meridien Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Compass Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33709"
                    }, 
                    "name": "Meridien Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33409"
                    }, 
                    "name": "Comprehensive Clinical Trials LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Annapolis", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21401"
                    }, 
                    "name": "Annapolis Sexual Wellness Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lutherville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21093"
                    }, 
                    "name": "Maryland Center for Sexual Wellness"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Queenstown", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21658"
                    }, 
                    "name": "Maryland Primary Care Physicians"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fall River", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02720"
                    }, 
                    "name": "NECCR Fall River LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19224"
                    }, 
                    "name": "Philadelphia Clinical Research, LLC"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Investigate the Safety and Efficacy of Lybridos in the Domestic Setting in Healthy Female Subjects With Hypoactive Sexual Desire Disorder and Maladaptive Activity of Sexual Inhibitory Mechanisms", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Sexual satisfaction will be evaluated based on a global satisfaction assessment comparing the 4-week establishment period with the 8 week DB treatment period. In addition there is a 8 week run in period between the establishment period and the double blind treatment period for a total treatment period of 20 weeks.", 
            "measure": "The primary endpoint is the number of satisfactory sexual episodes, measured using the Sexual Satisfaction of an Event Questionnaire (SSEQ).", 
            "safety_issue": "No", 
            "time_frame": "20 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101203"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Sexual satisfaction will be evaluated based on a global satisfaction assessment comparing the 4-week establishment period with the 8 week DB treatment period. In addition there is a 8 week run in period between the establishment period and the double blind treatment period for a total treatment period of 20 weeks", 
                "measure": "Sexual Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "20 weeks"
            }, 
            {
                "description": "Sexual desire and arousal will be evaluated based on the 'desire' and 'arousal' domains of the Sexual Anamnesis Questionnaire, the Sexual Function questionnaire and weekly diaries throughout the course of the study.", 
                "measure": "Sexual desire and arousal", 
                "safety_issue": "No", 
                "time_frame": "20 weeks"
            }, 
            {
                "description": "Sexual Distress will be assessed using the Female Sexual Distress Scale-Revised (FSDS-R).", 
                "measure": "Sexual Distress", 
                "safety_issue": "No", 
                "time_frame": "20 weeks"
            }, 
            {
                "description": "Using the following tools, perceived gain and improvement will be assessed:\nSubjective Evaluation of Gain (SEG)\nSubjective Evaluation of Improvement (SEI)\nPatient's Global Impression of Improvement (PGI-I)\nPatient Benefit Evaluation (PBE)", 
                "measure": "Subjective evaluation of gain and improvement", 
                "safety_issue": "No", 
                "time_frame": "20 weeks"
            }
        ], 
        "source": "Emotional Brain NY Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Emotional Brain NY Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}